In ROP, the tiny blood vessels in the back of the eye, called the retina, start to grow in a strange way. These blood vessels are supposed to help the eye see, but when they grow wrong ...

With the Trump administration making sweeping cuts to staff and research grants at science-related agencies, artificial ...

The infant is predisposed to phase 1 ROP due to an inherent lack of normally ... grow through the ridge toward the center of the eye (intravitreous) instead of following their normal growth ...

We recently published an article titled Charles Akre’s and John Neff’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Roper Technologies, Inc. (NASDAQ ...

The incidence of ROP in neonatal intensive care unit (NICU ... such as health education and promotion, accessible eye care services, strengthening of infrastructure and affordable technology ...

According to Precedence Research, the global newborn eye imaging systems market size is expected to be worth over USD 3.04 billion by 2034, up from USD 1.91 billion in 2025. Driven by significant ...

If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.